| Literature DB >> 33801702 |
Júllia A S Nascimento1, Fernanda F Santos1,2, Tiago B Valiatti1,2, José F Santos-Neto1, Ana Carolina M Santos1, Rodrigo Cayô2,3, Ana C Gales2, Tânia A T Gomes1.
Abstract
(1) Background: Hybrid uropathogenic Escherichia coli (UPEC) strains carry virulence markers of the diarrheagenic E. coli (DEC) pathotypes, which may increase their virulence potential. This study analyzed the frequency and virulence potential of hybrid strains among 452 UPEC strains. (2)Entities:
Keywords: DEC virulence markers; UPEC; antimicrobial resistance; hybrid strains; urinary tract infection
Year: 2021 PMID: 33801702 PMCID: PMC8065829 DOI: 10.3390/microorganisms9040693
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Genetic markers of diarrheagenic Escherichia coli (DEC) pathotypes used in the classification of uropathogenic E. coli (UPEC) as a hybrid strain, and results obtained by virulence phenotypic tests.
| Strain | Pathotype Genetic Markers | Hybrid Classification | Phylogroup | Adherence Pattern c | Hemolysis d | Biofilm Formation/Medium e | |||
|---|---|---|---|---|---|---|---|---|---|
| DEC | ExPEC a | UPEC b | DMEM | LB | |||||
| HSP 60 |
| UPEC/EAEC | D | NC | + ( | + | + | ||
| HSP 93 |
|
| UPEC/EAEC | A | NC | + ( | − | + | |
| HSP 117 |
|
| UPEC/EAEC | A | NC | + ( | + | - | |
| HSP 199 |
| - | - | UPEC/EAEC | B1 | AA | _ | − | + |
| HSP 215 |
|
| UPEC/EAEC | A | NC | + ( | + | + | |
| HSP 414 |
| - |
| UPEC/EAEC | B1 | AA | - | + | − |
| HSP 425 |
|
| UPEC/EAEC | A | NC | + ( | − | + | |
| HSP 278 |
|
|
| UPEC/aEPEC | A | LAL | − | − | − |
| HSP 446 |
| - |
| UPEC/aEPEC | B1 | LAL | − | − | − |
a Presence of at least two among five (pap, afa/dra, sfa, kpsMTII, and iut/iuc) genes determine the intrinsic virulence of the strains. b Simultaneous presence of vat, chuA, fyuA, and yfcV determines the uropathogenic potential of the strains. c As determined in HeLa cells. NC: non-characteristic aggregative adherence pattern; AA: aggregative adherence; LAL: localized adherence-like. d Assessed after incubation for 3 h, 6 h, and 24 h on washed blood agar containing 10 mM CaCl2; positive hemolytic strains detected in 3 h of incubation, except for HSP 425, which was detected after 6 h; hly+: presence of the hlyA gene. e DMEM, Dulbecco Minimal Essential Medium; LB: Lysogeny Broth; (+) biofilm formation; (−): lack of biofilm formation.
Pathotype, infection type a, additional information, age and gender of the patients carrying hybrid Escherichia coli isolated from urinary tract infections.
| Strain | Pathotype | Diagnosis | Additional Information | Age/Gender |
|---|---|---|---|---|
| HSP 60 | UPEC/EAEC | Cystitis | None | 85/female |
| HSP 93 | UPEC/EAEC | Cystitis | None | 26/female |
| HSP 117 | UPEC/EAEC | Cystitis | None | 40/female |
| HSP 199 | UPEC/EAEC | Pyelonephritis | Recurrent UTIs c | 66/female |
| HSP 215 | UPEC/EAEC | Cystitis | Recurrent UTIs c | 39/female |
| HSP 414 | UPEC/EAEC | Cystitis | None | 58/female |
| HSP 425 | UPEC/EAEC | Unavailable b | Chronic renal disease | 61/male |
| HSP 278 | UPEC/EPEC | Cystitis | None | 22/female |
| HSP 446 | UPEC/EPEC | Unavailable | Oncological inpatient | 4/female |
a Types of urinary tract infection and the medical conditions were reported as they were described in the anonymized medical records. b The anonymized medical records of chronic renal inpatients and oncological inpatients were not available. c Urinary tract infections.
Figure 1Phenotype of hemolytic activity of hybrid Escherichia coli strains isolated from urinary tract infection on tryptic soy broth agar supplemented with CaCl2 and washed defibrinated sheep blood after 24 h of incubation at 37 °C. E. coli strains used as controls: EDL933 (enterohemolysin-producer), J96 (alpha-hemolysin producer), and C600 (nonhemolytic).
Figure 2Adherence patterns of representative hybrid uropathogenic Escherichia coli (UPEC) strains. The adherence patterns were assessed as preconized in HeLa cells in assays with an incubation period of 3 h or 6 h, at 37 °C in the presence of 2% D-mannose, using a multiplicity of infection of 10. The preparations were stained with May-Grünwald/Giemsa and observed under a light optical microscope (1000× magnification). All hybrid UPEC strains were adherent, and different adherence patterns were identified. Representative hybrid UPEC/EAEC (enteroaggregative E. coli) strains (3 h) are in panels (A,B), and a hybrid UPEC/aEPEC (atypical enteropathogenic E. coli) strain (6 h) in panel (C). (A). HSP 117, displaying a non-characteristic aggregative adherence pattern with small loose clusters and spread foci of adherent bacteria; (B). HSP 414, showing the typical aggregative adherence pattern; (C). HSP 278, showing the localized adherence-like pattern. (D). E. coli 042 (EAEC—aggregative adherence pattern control); (E). E. coli strain E2348/69 (typical EPEC—localized adherence pattern control); (F). E. coli strain 4581-2 (aEPEC—localized adherence-like pattern control); (G). E. coli strain CFT073 (UPEC control); (H). E. coli strain HB101 (K-12 derived laboratory strain, non-adherent control); (I). Non-infected control cells.
Figure 3Interaction with a renal origin cell-lineage. The hybrid uropathogenic Escherichia coli (UPEC) strains’ capacity to interact with human renal cells was assessed using HEK 293T cells in assays with an incubation period of 3 h, at 37 °C without D-mannose, using a multiplicity of infection of 10. The preparations were stained with May-Grünwald/Giemsa and observed under a light optical microscope (1000× magnification). Representative hybrid UPEC/EAEC (enteroaggregative E. coli) strains are in panels (A,B), and a hybrid UPEC/aEPEC (atypical enteropathogenic E. coli) strain in panel (C). All hybrid UPEC strains interacted with renal cells in diverse intensity; in panel (A), the HEK 293T cell monolayer was partially detached, and pyknotic nuclei were observed in the remaining cells; the same phenotype was observed in panel (G), with CFT073, a UPEC control strain, which produces hemolysin. (A) HSP 117; (B) HSP 414; (C) HSP 278; (D) E. coli strain 042 (EAEC control); (E) E. coli strain E2348/69 (typical EPEC control); (F) E. coli strain 4581-2 (aEPEC control); (G) E. coli strain CFT073 (UPEC control); (H) E. coli strain HB101 (E. coli K-12 derived laboratory strain, non-adherent control); (I) Non-infected control cells.
Figure 4Biofilm formation with incubation period of 24 h, in Dulbecco Modified Essential Medium (DMEM) + GlutaMAX medium (A) and Lysogeny-Broth (LB) (B). Positive control: EAEC (enteroaggregative E. coli) prototype strain 042; Negative control: non-adherent E. coli strain HB101. The absorbance reading was performed at 620 nm. The One-way ANOVA followed by post-hoc Tukey HSD test was used to compare the results. p values: * < 0.05; ** < 0.01; *** < 0.001; **** p < 0.0001; ns > 0.05. The results were obtained from the average of a biological triplicate.
Antimicrobial susceptibility profile and β-lactamase-encoding genes content in the nine hybrid uropathogenic Escherichia coli (UPEC) strains.
| Strain | ESBL Gene | CAZ | FEP | CRO | ATM | MEM | ETP | IMI | APS | LEV | CIP | AMK | GEN | MIN | TGC | COL | PMB |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HSP 60 | 0.5 | 1 | 0.5 | 0.125 | <0.06 | <0.06 | 0.5 |
| 0.06 | 0.125 |
|
| 16 | 0.125 | <0.25 | <0.25 | |
| HSP 93 | <0.125 | <0.125 | 1 | <0.06 | <0.06 | <0.06 | <0.06 | 08/4 | 0.06 | 0.06 | 1 | 0.5 | 0.5 | 0.125 | <0.25 | <0.25 | |
| HSP 117 | <0.125 | <0.125 | 0.5 | 0.125 | <0.06 | <0.06 | <0.06 | 02/4 | 0.5 |
| 8 | 0.5 | 8 | 0.25 | <0.25 | <0.25 | |
| HSP 199 | 0.5 | 0.25 | 1 | <0.06 | <0.06 | <0.06 |
|
|
|
|
|
| 2 | 0.125 | <0.25 | <0.25 | |
| HSP 215 | <0.125 | <0.125 | 1 | <0.06 | <0.06 | <0.06 | <0.06 | 16/4 | 0.06 | 0.06 | 1 | 0.5 | 0.5 | 0.125 | 0.5 | <0.25 | |
| HSP 425 | <0.125 | <0.125 |
| 1 | <0.06 | <0.06 | <0.06 | 04/4 | 0.06 | <0.03 | 1 | 1 | 1 | 0.125 | <0.25 | <0.25 | |
| HSP 278 | <0.125 | <0.125 | 0.5 | 0.125 | <0.06 | 0.5 | 0.125 |
| 0.5 | 0.06 | 256 | >256 | 8 | 0.125 | <0.25 | <0.25 | |
| HSP 446 |
|
|
|
|
| <0.06 | 0.125 | 0.5 |
| 0.25 |
| 2 |
| 16 | 0.25 | <0.25 | <0.25 |
Abbreviations: AMK, amikacin; APS, ampicillin/sulbactam; ATM, aztreonam; CAZ, ceftazidime; CIP, ciprofloxacin; CRO, ceftriaxone; CST, colistin; ETP, ertapenem; FEP, cefepime; IPM, imipenem; GEN, gentamicin; MEM, meropenem; LEV, levofloxacin; MIN, minocycline; PMB, polymyxin B; TGC, tigecycline; COL, colistin. Numbers in bold represent the resistant phenotype according to BrCAST breakpoints.